Zymeworks (ZYME) Return on Capital Employed (2022 - 2026)
Zymeworks (ZYME) reported Return on Capital Employed of 30.28% for Q1 2026, up 267.0% on a YoY basis from 8.25% in Q1 2025, and down 7.81% sequentially from 28.08% in Q4 2025.
Zymeworks (ZYME) Return on Capital Employed (2022 - 2026) Analysis & Trends
Zymeworks (ZYME) has 5 years of Return on Capital Employed data on file, last reported at 30.28% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 267.0% year-over-year to 30.28%; the trailing twelve-month figure through Mar 2026 stood at 30.28% (up 267.0% YoY), and the FY2025 full-year result was 25.53%, up 608.0% from the prior year.
- Return on Capital Employed eased to 30.28% in Q1 2026, from 28.08% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 40.44% in Q3 2023 to a low of 35.44% in Q4 2024.
- A 5-year average of 10.18% and a median of 27.5% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 7357 bps in 2024 and surged 1356 bps in 2025, its largest moves.
- Tracing ZYME's Return on Capital Employed over 5 years: stood at 34.45% in 2022, then sank by 178 bps to 26.92% in 2023, then slumped by 32 bps to 35.44% in 2024, then rose by 21 bps to 28.08% in 2025, then slipped by 8 bps to 30.28% in 2026.
- Business Quant data shows ZYME's Return on Capital Employed at 30.28% in Q1 2026, 28.08% in Q4 2025, and 19.57% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Zymeworks | 1.70 Bn | 1.34 Bn | - | -30.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.28% |
| Dec 31, 2025 | -28.08% |
| Sep 30, 2025 | -19.57% |
| Jun 30, 2025 | -21.85% |
| Mar 31, 2025 | -32.94% |
| Dec 31, 2024 | -35.44% |
| Sep 30, 2024 | -33.13% |
| Jun 30, 2024 | -28.61% |
| Mar 31, 2024 | -29.11% |
| Dec 31, 2023 | -26.92% |
| Sep 30, 2023 | 40.44% |
| Jun 30, 2023 | 36.95% |
| Mar 31, 2023 | 31.56% |
| Dec 31, 2022 | 34.45% |